{"entity":{"id":"catumaxomab","kind":"drug","name":"Catumaxomab","aka":["Removab (2009 to 2017)"],"tldr":"Catumaxomab (Korjuny) is an antibody infused into the abdominal cavity to control malignant ascites, the build-up of fluid caused by cancers such as ovarian and stomach cancer, in people whose other treatments have stopped working.","summary":"Catumaxomab was the first bispecific antibody approved anywhere, authorised in the EU in 2009 as Removab for malignant ascites in EpCAM-positive carcinomas on a randomised trial against paracentesis alone in which puncture-free survival was quadrupled. Its marketing authorisation was withdrawn in 2017 for commercial reasons after the original company failed, and a new authorisation was granted to Korjuny in February 2025 for intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas not eligible for further systemic anticancer therapy. It is given as four intraperitoneal infusions over about ten days. Cytokine release-type reactions (fever, nausea, vomiting, abdominal pain) are almost universal and hepatic enzyme rises are common; it has never been approved in the US.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Catumaxomab","links":[{"label":"EPAR (EMA)","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny"}],"tags":["ema-list","supportive"],"related":[],"cancers":["ovarian","gastric","pancreatic","colorectal"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["epcam","cd3"],"drugs":[],"companies":["lindis-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct00377429","nct00189345","nct00563836"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Korjuny","modality":"Trifunctional bispecific antibody (EpCAM x CD3, rat-mouse hybrid)","mechanism":"Binds EpCAM on tumour cells and CD3 on T cells while its Fc region engages Fc-gamma receptor-positive accessory cells, killing EpCAM-positive cells in the peritoneal cavity by T-cell cytotoxicity, phagocytosis and antibody-dependent mechanisms.","approvals":[{"region":"EU","year":2009,"indication":"Malignant ascites in EpCAM-positive carcinomas when standard therapy is unavailable (Removab; withdrawn 2017)"},{"region":"EU","year":2025,"indication":"Intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas not eligible for further systemic therapy (Korjuny)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/catumaxomab/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/"}],"company":[{"id":"lindis-biotech","kind":"company","name":"Lindis Biotech","route":"/companies/lindis-biotech/"}],"trial":[{"id":"nct00563836","kind":"trial","name":"Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer","route":"/trials/nct00563836/"},{"id":"nct00189345","kind":"trial","name":"Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients","route":"/trials/nct00189345/"},{"id":"nct00377429","kind":"trial","name":"Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy","route":"/trials/nct00377429/"}]}}